Tuesday is shaping up to be a good day for bioAffinity Technologies Inc. (BIAF). The company's stock is trading sharply higher as it pushes forward with a new application for its CyPath Lung test: keeping an eye on lung cancer survivors after they've finished treatment.
For people who've beaten lung cancer, the worry doesn't end with remission. Recurrence is a real and persistent threat, and catching it early is crucial. That's where bioAffinity wants to step in. The company is developing CyPath Lung as a surveillance tool for patients who have completed curative-intent therapy, essentially giving doctors a noninvasive way to monitor for signs of the disease coming back.
The Numbers Behind the Need
The scale of the problem is significant. According to the American Cancer Society, more than 680,000 Americans were living with a prior lung cancer diagnosis as of January 1, 2025. And the National Cancer Institute projects that healthcare providers will diagnose 230,000 new patients in 2026 alone. That's a lot of people who will eventually need monitoring.
bioAffinity Technologies focuses on noninvasive early-stage diagnostics for lung diseases, along with broad-spectrum cancer treatments. The company's approach is all about catching problems before they become bigger ones, and doing it without invasive procedures.
How CyPath Lung Works
CyPath Lung is designed to enhance early detection in high-risk individuals. The test uses advanced flow cytometry paired with proprietary artificial intelligence to identify malignant cell populations in sputum samples. It also incorporates a specialized fluorescent porphyrin that cancer and cancer-related cells preferentially absorb, making them easier to spot.
The idea is simple: a noninvasive test that can flag potential issues early, giving doctors and patients more information without the need for more aggressive procedures.
What the Data Shows
In published clinical trials involving high-risk patients with indeterminate nodules under 20 millimeters, CyPath Lung demonstrated impressive metrics: 92% sensitivity, 87% specificity, 88% accuracy, and a 99% negative predictive value. That last number is particularly important. A high negative predictive value means that when the test says there's no cancer, doctors can be highly confident that's correct. This could spare patients from unnecessary and costly invasive procedures.
However, these results come from initial detection settings. The company notes that separate validation is needed for post-treatment monitoring. So while the early data is encouraging, the surveillance application will require its own clinical evidence.
CyPath Lung is marketed as a Laboratory Developed Test, meaning it's meant to complement other clinical findings rather than stand alone as a definitive diagnosis. It's another tool in the doctor's toolkit, not a replacement for professional judgment.
Stock Reaction
Investors seem to like what they're hearing. At the time of publication on Tuesday, bioAffinity Technologies shares were up 42.98% at $6.52. That's a big move, though the stock is still trading near its 52-week low of $4.55, according to market data.
It's a reminder that in the world of biotech, a single piece of news can send shares soaring, but the underlying fundamentals and long-term prospects are what ultimately matter. For bioAffinity, the path forward involves proving that CyPath Lung can deliver on its promise in the post-treatment setting, and that will take time and data.
